Background: Co-morbid depression is a serious condition in patients with diabetes that negatively affects their self-management, including drug adherence, consequently, the treatment outcomes and quality of life are also affected.
resulting from defects in insulin secretion, insulin utilization, or both [1] . The vast majority of diabetes is type 2 diabetes comprising about 90% of cases [1] .
Diabetes is a chronic disease which affects virtually every organ in the human system. The global prevalence of diabetes is continuously rising and the World Health Organization (WHO) projected that 300 million people will suffer from diabetes by 2025 [2] .
The prevalence of diabetes in sub-Saharan Africa is expected to triple by 2030, making it a cause for concern not only for health professionals but also policy makers as they initiate strategies to tackle it [3] .
Kenya, like other developing countries, is experiencing this emerging diabetes epidemic. It is estimated that the prevalence of diabetes in the country is about 3.3%. This figure is projected to rise to 4.5% by 2025 if this trend continues, according to Kenya National Diabetes Strategy [4] . Diabetes-related co-morbidities and complications are expected to rise in parallel with the rising numbers of diabetes.
Depression is a chronic psychopathological state that involves a triad of symptoms with low or depressed mood, anhedonia, and low energy or fatigue. Other symptoms, such as sleep and psychomotor disturbances, feeling of guilt, low self-esteem, suicidal tendencies, as well as autonomic and gastrointestinal disturbances, are also present [5] .
The lifetime prevalence of depression is as high as 20% in the general population worldwide with a female to male ratio of about 5:2 [5] . According to WHO, depression is ranked as the fourth global burden of disease, responsible for the greatest proportion of burden associated with non-fatal health outcomes and account for approximately 12% of total years lived with disability [6] . It is predicted to become second only to ischemic heart disease as a cause of morbidity worldwide [7] .
Patients with type -2 diabetes have a rate of major depression 1.6-2 times higher than those in the general population affecting one in every 10 diabetic patients [8] .
Diabetes distress (concerns and worries of diabetes and its management) is associated with depressive symptoms [9] . Co-morbid depression is associated with poor self-care [10] , poor adherence to
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Significance of the Study
Depression is a serious co-morbid condition in diabetes patients that negatively affects self-management, drug adherence, treatment outcomes and quality of life. Knowing the burden of the clinical condition heralds the first step to managing it. There are scarce published data on depression in ambulatory type 2 diabetes in this region. Therefore the study was done to determine the prevalence and severity of co-morbid depression in ambulatory type 2 diabetes patients at KNH and to document their socio-demographic and clinical characteristics.
Methods
This was a descriptive cross-sectional study that we conducted at the diabetes out-patient clinics in KNH. The study population consisted of patients of age ≥ 30 yrs with a diagnosis of type 2 diabetes for ≥ 1 year and followed up at the diabetes clinic. We used a systematic sampling method to recruit the subjects wherein every 2 patient on the minor clinic day and every 4 th on the major clinic day that met the inclusion criteria was selected (Figure 1 ).
To collect socio-demographic and clinical data standard questionnaire was used. Patient Health Questionnaire 9 (PHQ-9), was used to assess symptoms of depression [16] (Table 1 ) (Appendix). PHQ-9 assesses the extent of bother by symptoms of Depressive illness in the previous two (2) weeks on a Likert scale (not-at-all to nearly-every-day). The symptoms range from interest or pleasure in doing tasks, feeling of hopelessness, trouble falling asleep, feeling tired, feeling bad about self, trouble with concentration, slow speaking or restlessness and a feeling of being better dead. The last, tenth, question on the PHQ-9 tool used performs Functional Health Assessment by seeking to know the psychosocial functioning of the study subjects is affected by the emotional difficulties. PHQ-9 has been validated locally and there is a Kiswahili translation available. The standard mercury sphygmomanometer was used to measure Blood Pressure (mmHg), weighing scale for weight (kilograms) and a stadiometer to measure height (meters).
Inclusion criteria
1. The patients of age ≥ 30 years with a documented diagnosis of type 2 diabetes of ≥ 1 year attending the diabetes clinic and gave informed consent.
2. Participants who were able to speak and understand Kiswahili and/or English.
Exclusion criteria
The patients with psychiatric illness other than depression and patients who did not consent to participate were excluded.
Sample size determination
Using the Cochran formula [17] , a sample size of 220 diabetic mellitus patients was calculated to estimate prevalence of co-morbid depression at 95% confidence interval within 6.2% precision error.
Definition of study variables
Depression: PHQ-9 score of ≥ 10 was described as presence of clinical depression, a level of score at which there was optimal discriminatory power to make diagnosis of Major Depressive illness [16] .
Severity of depression:
Clinical depression was categorized into Moderate (10) (11) (12) (13) (14) , moderately severe (15) (16) (17) (18) (19) and Severe (20-27) based on the PHQ-9 scores in the brackets. Blood pressure: A subject was considered to have arterial hypertension if he/she was a on blood pressure lowering drugs model to determine factors independently associated with co-morbid depression while controlling for confounding effects. The statistical tests were performed at 5% level of significance (p value less or equal to 0.05 will be interpreted as significant) ( Table 2 and Table 3 ).
Ethical Considerations
Permission and approval was obtained from the Department of Clinical Medicine and Therapeutics of the University of Nairobi and the Institution's Ethical Review Committee for research, before data collection.
We obtained consent from the study subjects after providing them with adequate information about the study. Blood pressure, BMI and HBA 1C results were communicated to patients as well as their primary physicians for clinical decision-making. Those who were found to have depression were referred to the mental health department for further care. Blood samples were used only for the intended purpose and were discarded after the study.
Results
A total of 220 participants with type 2 diabetes mellitus were recruited into the study. Below is a summary of their characteristics.
Discussion
The study was set to determine the burden of co-morbid depression in ambulatory patients living with type 2 diabetes at the diabetes out-patient clinic of KNH using the PHQ-9 questionnaire.
The prevalence of co-morbid depression in the study subjects in the out-patient clinic of this hospital was found to be 32.3%, 95% CI 26.4-38.6%, and more than half (18.7%) of them had moderate to severe depression. This is a significant proportion of people already afflicted by a chronic disease (Figure 2 ). This prevalence of co-morbid depression is lower than that reported in a cross-sectional study by Ndetei DM et al. [21] , also done in Kenya which included 2,770 general medical out-patients across 10 different health facilities. They reported that 42.3% of their study patients had clinical depression using BDI [21] . The cohort of patients in the study of Ndetei et al. had various diagnostic labels that included, but not limited to, cancers, respiratory diseases, cardiovascular diseases, diabetes, and HIV disease. More than half of the patients suffering from cancer (59.6%) and HIV/AIDS (52.2%) had co-morbid depression. The heterogeneous diagnostic labels and data collection tool would probably explain the observed differences in prevalence of depression compared to our study. from the hospital records. For subjects with no prior history of hypertension, a blood pressure ≥ 140/90 mmHg was considered to have hypertension. (JNC 8 Guidelines 2014) [19] . 
Data analysis
Statistical analysis was done using IBM SPSS statistics v21 (2012). Prevalence of co-morbid depression was calculated and presented as a percentage of the total study subjects, at 95% confidence interval. In addition, the proportion with co-morbid depression was presented as percentages. Factors associated with depression were analyzed using Chi square tests and odds ratios (OR). Statistically significant factors in the univariate associations were put in binary logistic regression Table 3 : Independent factors associated with Co -morbid Depression in the study subjects.
Variable
Adjusted OR (95% CI) P value Age group (years)
-44
45 -54
-64
≥ 65 The parameters of age, duration of diabetes and obesity that were previously, in univariate analysis, significantly associated with Co -morbid Depression cease to be, except for quality of glycaemic control, in the regression model. The overall prevalence of co-morbid depression in our study was comparable to other studies done in sub-Saharan Africa on patients with type 2 diabetes in the out-patient setting. Teklay et al. in Ethiopia found a prevalence of 33% using PHQ-9, in their cross-sectional, hospital-based study of 267 diabetic out-patients, 2011 [22] , Camara A. et al. in Guinea found a prevalence of 34.4%, using HADS tool in a cross-sectional, hospital-based study, 2014 [23] , and Akena D. et al. in Uganda, in their cross-sectional survey used PHQ-9 on patients with type 2 diabetes and found a prevalence of co-morbid depression of 34.8% [24] . This similarity in the prevalence of co-morbid depression in patients with type 2 diabetes may be due to shared psycho-social stressors among sub-Saharan Africans. The countries in sub-Saharan Africa share health system challenges and comparable poverty indices of their populations that may help explain part of this similarity in prevalence. However the prevalence of depression in our study was lower than that reported by Amit R et al. in India [25] , of 41%, using PHQ-9 in a cross-sectional hospital-based study, 2009. It was relatively higher than the prevalence reported by studies in the developed world on patients with type2 diabetes. Ali S. et al. in the UK [26] reported a prevalence of 9.3%, using CESD tool in their cross-sectional study, 2009 and Chaoyang Li et al. in the USA [27] found a prevalence of 8.3%, using PHQ-9 in their population-based survey, 2008.
Duration of diabetes (years)
The prevalence reported in these studies differ, probably due to variation in characteristics of study participants coming from populations of multiple social and cross-cultural backgrounds, level of income of countries [28] use of different psychometric tools in studies with varying definitions of depression [29] , and the diversity in psycho-social stressors from one community to another in the many countries where the studies were conducted.
In our study, the mean age of subjects with co-morbid depression was 59.1 ± 8.5 years, similar to that of the overall study population of 57.1 ± 8.6 years. Forty five (45.5%) percent of the study patients aged above 65years had co-morbid depression compared to 15.8% of the younger age group of 35-44 years. Old age above 65yrs was significantly associated with presence of co-morbid depression. (p = 0.006) in univariate analysis. This age is associated with diabetesrelated complications, co-morbidities and therefore added hurdle in coping with diabetes care. Other investigators like Nitin J et al. in India in a cross-sectional study, 2010 [30] and Camara A. et al. in
Guinea [22] , had similar finding, but Akena D et al. [23] . In their cross-sectional study in Uganda, reported that their study subjects with co-morbid depression were younger, and they were also poorer and suicidal.
We found no significant association between gender and comorbid depression (p = 0.130), apparently fewer females (28.5%) had depressive symptoms than the males (38.2%) in this study. We did not specifically interrogate the obtaining psycho-social support systems of our study subjects beyond knowing their marital and employment status. Even then, the marital status, employment and the level of formal education were not significantly associated with presence of co-morbid depression (p = 0.783, p = 0.110 and p = 0.261 respectively) in this study.
The study of Nitin J et al. in India [18] and a multicenter crosssectional study of Ali Khan et al. in Pakistan, 2010 [19] , both found female gender, among other risk factors, to be associated with comorbid depression. Katon WJ et al. [11] , in a longitudinal study, Tellez-Zenteno JF et al. [31] , in a cross-sectional study of 189 subjects in Mexico, found female gender, young age, poor psycho-social support, low formal education and socio-economic status, amongst other risk factors, were associated with presence of co-morbid Depression in their patients with type 2 diabetes.
Thirty nine, (39.3%) percent, of the study subjects who were either on combination (OGLAs + insulin) or insulin-only therapy, had co-morbid depression compared to 26.3% on OGLAs-only but there was no significant association between treatment groups and Co-morbid Depression. However, medication burden as well as daily insulin injections are potential stressors in the group of patients who are on injections.
We observed that high BMI ≥ 25 kg/m² (overweight and obese) was significantly associated with co-morbid depression (p = 0.035) in univariate, but collapsed in multivariate analysis. Obesity in some patients with diabetes: can be a consequence of reduced physical activities, an observation in those with co-morbid depression, as reported by Lin EH et al. [32] , and unhealthy diets, as reported by Dipnal JF et al. [33] . The tenth item on PHQ-9 tool assesses physical and psycho-social function. In this study, over 80% of the subjects with Co-morbid Depression reported difficulty with physical and psycho-social function of varying proportions. We did not explore the dietary discretions and physical activity status of our study patients (Figure 3 ).
There was a significant association between longer duration of diabetes (5yrs and above) and co-morbid depression. (p = 0.044). Other workers, Tapash et al. in a cross-sectional study, 2011, in Bangladesh [34] , Nitin J et al. in India [29] , Ali Khan et al. in Pakistan [35] also reported that longer duration of diabetes was significantly associated with co-morbid depression. The patients with longer duration of diabetes are more likely to have co-existing complications of diabetes and high disease burden with additional health care challenges. These factors are potential stressors sufficient to drive depression (or distress) in such patients with diabetes.
There was a significant association between presence of comorbid depression and poor glycemic control (p = 0.006). Many studies, for example, Bot et al. in a multicenter cross-sectional study in Netherlands [36] and Marcello et al. in a cross-sectional study in Brazil [37] , have reported the association of Depression with poor glycemic control in their study patients. This is an important observation that puts these patients at higher risk of complications associated with poor glycaemic control.
Conclusions
Co-morbid Depression occurred in 1 in 3 of the study subjects with type 2 diabetes, which is a fairly high prevalence. Poor glycaemic control was consistently associated with Co-morbid depression therefore, patients with type 2 diabetes should be screened for Co-morbid depression. However, other potential risk factors, (older age of 65 yrs and above, long duration of diabetes and presence of diabetes-related complications) should be screened for the same and treated.
